Siren, L.L.C. Portfolio Holdings

Siren, L.L.C.

  • $2.56 Trillion
  • Q3 2025

Siren, L.L.C. has filed its 13F form on November 13, 2025 for Q3 2025 where it was disclosed a total value porftolio of $2.56 Trillion distributed in 117 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Scholar Rock Holding Corp with a value of $344B, Kymera Therapeutics, Inc. with a value of $194B, Bei Gene, Ltd. with a value of $168B, Arrowhead Pharmaceuticals, Inc. with a value of $92.1B, and Bicara Therapeutics Inc with a value of $82.4B.

Examining the 13F form we can see an increase of $624B in the current position value, from $1.93T to 2.56T.

Siren, L.L.C. is based out at New York, NY

Below you can find more details about Siren, L.L.C. portfolio as well as his latest detailed transactions.

Portfolio value $2.56 Trillion
Technology: $123 Billion
Communication Services: $57.5 Billion
Consumer Cyclical: $21.1 Billion
Consumer Defensive: $5.26 Billion
Real Estate: $2.76 Billion
Financial Services: $938 Million
Industrials: $302 Million
Healthcare: $145 Million
Other: $0

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$1.95B
$344 Billion 13.48% of portfolio
9,250,005
Q4 2024 Reduced 17.85%
$3.55B
$194 Billion 7.59% of portfolio
3,428,150
Q2 2025 Added 5.8%
$23.5B
$168 Billion 6.57% of portfolio
492,990
Q3 2025 Reduced 3.33%
$4.37B
$92.1 Billion 3.6% of portfolio
2,669,880
Q1 2025 Reduced 7.99%
Bicara Therapeutics Inc
-
$82.4 Billion 3.22% of portfolio
-
Q2 2025 Added 59.68%
$2.6B
$78.3 Billion 3.06% of portfolio
3,227,517
Q3 2025 Reduced 6.72%
$2.34B
$70.3 Billion 2.75% of portfolio
1,688,611
Q1 2025 Added 4.91%
$1.44B
$63.2 Billion 2.47% of portfolio
3,897,099
Q3 2025 Added 23.31%
Disc Medicine Inc
-
$60.4 Billion 2.36% of portfolio
-
Q3 2025 Reduced 16.92%
$975M
$59.8 Billion 2.34% of portfolio
4,729,174
Q3 2025 Reduced 2.22%
$2.23B
$58.3 Billion 2.28% of portfolio
2,578,396
Q1 2025 Reduced 8.45%
$3.69B
$56 Billion 2.19% of portfolio
1,285,610
Q3 2025 Added 15.76%
$1.05B
$52.8 Billion 2.07% of portfolio
2,247,347
Q1 2025 Added 12.37%
$268M
$52.5 Billion 2.06% of portfolio
38,918,903
Q1 2025 Added 1,006.84%
$5.54B
$50.5 Billion 1.98% of portfolio
499,975
Q3 2025 Added 22.02%
$720M
$49.4 Billion 1.93% of portfolio
5,883,188
Q3 2025 Added 74.84%
$11.4B
$46.9 Billion 1.83% of portfolio
235,862
Q3 2025 Reduced 4.1%
$385M
$45.8 Billion 1.79% of portfolio
4,870,000
Q3 2025 New
Solid Biosciences Inc
-
$45.8 Billion 1.79% of portfolio
-
Q1 2025 Added 97.81%
Septerna Inc
-
$41.4 Billion 1.62% of portfolio
-
Q4 2024 New
$1.45B
$39.6 Billion 1.55% of portfolio
2,912,077
Q3 2025 Added 80.64%
$204M
$36 Billion 1.41% of portfolio
11,014,737
Q2 2025 Added 69.07%
$965M
$34 Billion 1.33% of portfolio
9,969,495
Q3 2024 New
$2.54B
$32.6 Billion 1.28% of portfolio
812,761
Q2 2025 Added 10.92%
Soleno Therapeutics Inc
-
$31.6 Billion 1.24% of portfolio
-
Q2 2025 Reduced 35.75%
Rapport Therapeutics Inc
-
$31.3 Billion 1.22% of portfolio
-
Q3 2025 Added 178.35%
Structure Therapeutics Inc
-
$28.8 Billion 1.12% of portfolio
-
Q3 2025 New
$600M
$27.1 Billion 1.06% of portfolio
3,696,322
Q1 2025 Reduced 1.44%
$2.09B
$26.4 Billion 1.03% of portfolio
1,618,271
Q3 2025 Added 213.95%
$2.21B
$24.8 Billion 0.97% of portfolio
1,724,279
Q3 2025 Added 101.82%
$661M
$23.2 Billion 0.91% of portfolio
2,536,867
Q3 2025 Reduced 35.59%
-
$21.8 Billion 0.85% of portfolio
-
Q3 2025 Reduced 35.88%
Korro Bio Inc
-
$20.1 Billion 0.78% of portfolio
-
Q3 2024 New
$315M
$19.1 Billion 0.75% of portfolio
8,757,249
Q1 2025 Reduced 1.13%
$2.07B
$16.1 Billion 0.63% of portfolio
2,357,520
Q3 2024 New
$1.4B
$16.1 Billion 0.63% of portfolio
275,200
Q3 2025 New
$192M
$15.6 Billion 0.61% of portfolio
2,012,752
Q2 2025 Added 11.03%
Rapt Therapeutics Inc
-
$15 Billion 0.59% of portfolio
-
Q3 2025 New
$247M
$15.1 Billion 0.59% of portfolio
2,911,438
Q2 2025 Added 4.36%
Upstream Bio Inc
-
$14.8 Billion 0.58% of portfolio
-
Q1 2025 Reduced 1.44%
$255M
$13.7 Billion 0.54% of portfolio
5,208,968
Q4 2024 Reduced 60.78%
Arrivent Biopharma Inc
-
$12.9 Billion 0.51% of portfolio
-
Q2 2025 New
$2.39T
$12.8 Billion 0.5% of portfolio
58,500
Q3 2025 Added 3.54%
$518M
$12.1 Billion 0.47% of portfolio
1,007,575
Q3 2024 New
$2.34B
$11.9 Billion 0.47% of portfolio
821,513
Q1 2025 Reduced 1.5%
$9.4B
$10.5 Billion 0.41% of portfolio
170,000
Q4 2024 Reduced 66.0%
Sionna Therapeutics Inc
-
$9.56 Billion 0.37% of portfolio
-
Q1 2025 New
$3.78T
$8.88 Billion 0.35% of portfolio
17,150
Q3 2025 Added 6.19%
$115B
$9.07 Billion 0.35% of portfolio
18,500
Q2 2025 Reduced 26.0%

Summary

  • Portfolio
  • No. of Stocks 117
  • Current Value $2.56 Trillion
  • Prior Value $1.93 Trillion
  • Filing
  • Period Q3 2025
  • Filing Date November 13, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 24 stocks
  • Additional Purchases 24 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 14 stocks
Track This Portfolio

Track Siren, L.L.C. Portfolio

Follow Siren, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Siren, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Siren, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email